Navigation Links
Florida Man Develops Bladder Cancer as Result of Taking Actos, Alleges Lawsuit Filed by Parker Waichman LLP
Date:6/24/2013

New York, NY (PRWEB) June 24, 2013

Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, has filed a lawsuit on behalf of a Florida man who developed bladder cancer after taking the diabetes drug Actos (pioglitazone). The suit was filed on May 23, 2013 in the U.S. District Court for the Western District of Louisiana (Case No. 6:13-cv-1236). It is one of thousands of cases that have been filed into the multidistrict litigation (MDL) entitled In Re: Actos (Pioglitazone) Products Liability Litigation (6:11-md-2299). Takeda Pharmaceuticals, America; Takeda Pharmaceuticals USA, Inc. f/k/a Takeda Pharmaceuticals North America, Inc.; Takeda Pharmaceutical Company Limited; and Eli Lilly and Company have been named as Defendants.

According to the Complaint, the Plaintiff took Actos to treat his Type 2 diabetes from January 2002 to April 2005, when he was diagnosed with bladder cancer. The lawsuit alleges that his bladder cancer was due to the side effects of Actos. Additionally, the suit alleges that the Defendants knew about the risk of bladder cancer but did not disclose this information to consumers in order to protect financial interests. The Plaintiff alleges that Actos caused pain and suffering, emotional distress and economic damages in the form of medical expenses and lost wages. The suit is also seeking damages for loss of consortium on behalf of the Plaintiff’s spouse.

In June 2011, the U.S. Food and Drug Administration (FDA) warned that taking Actos for more than a year could significantly increase the risk of bladder cancer and announced that the label would be updated to reflect this risk. This warning was based on an ongoing 10-year study by Kaiser Permanente. (http://www.fda.gov/Drugs/DrugSafety/ucm266555.htm)

Several studies support the link between Actos and bladder cancer. Last May, a study in the British Medical Journal found that Actos users were twice as likely to develop bladder cancer after two years. That July, the Canadian Medical Association Journal found that patients taking the medication were 22 percent more likely to get bladder cancer. (http://www.bmj.com/content/344/bmj.e3645) (http://www.cmaj.ca/content/early/2012/07/03/cmaj.112102)

Parker Waichman LLP continues to offer free legal consultations to victims of Actos injuries, including bladder cancer, heart problems, and eye injuries. If you or a loved one were diagnosed with bladder cancer after taking Actos, please contact their office by visiting yourlawyer.com. Free case evaluations are also available by calling 1 800 LAW INFO (1-800-529-4636).

Contact:
Parker Waichman LLP
Gary Falkowitz, Managing Attorney
(800) LAW-INFO
(800) 529-4636
http://www.yourlawyer.com

Read the full story at http://www.prweb.com/releases/actos-bladdercancer-claim/06/prweb10859164.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Into Action Drug and Alcohol Treatment Center Donates Tiles to RiseUP Gallery in Miami, Florida
2. Florida Lawmakers Agenda Against the Future of Medical and Recreational Marijuana in Florida May Have Severe Repercussions, as Reported by PotStores.com
3. Key West, Florida Joins Best Halfway House Recovery Network, Helping People Seek Further Recovery from Drug and Alcohol Addiction
4. Nemours Pediatric ENT Performs Minimally Invasive Procedure on South Florida Boy at Wolfson Children’s Hospital in Jacksonville, FL
5. Pensacola, Florida Joins Best Halfway House Recovery Network, Providing Resources for Those Seeking to Further Their Recovery from Drug and Alcohol Addiction
6. Florida Athletes Prepare for National Veteran Wheelchair Games in Tampa
7. Controversial Detox Center Billboard Appearing in South Florida
8. The Women’s Board of Wolfson Children’s Hospital Announces 2013-2014 Florida Forum Lineup
9. US Sports Camps Announces NIKE Baseball Camps to Host Two New Camp Locations in Florida
10. South Florida's Most Popular Dermatologist Dr. Flor Mayoral Launches New Website at MayoralDerm.com
11. US Drug Watchdog Now Urges All Florida Recipients of a Recalled DePuy ASR XL Hip Implant to Call Them Immediately if They Have Not Yet Been Identified by a Law Firm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... ... , ... In the United States, 20 million women and 10 million men ... feel shame for having struggled with an eating disorder as well as common co-occurring ... in Life After an Eating Disorder” -- to be featured at this year’s iaedp ...
(Date:1/20/2017)... ... ... A new partnership between Goodwill® and Roadie, Inc. aims to make it easier ... couches to dressers and bicycles. Roadie — the national on-the-way delivery network — will ... through February 28th. , “January is an exciting time when resolutions are made ...
(Date:1/20/2017)... ... , ... Doctor C LLC, a company based out of Arizona that focuses ... the marketing and distribution of its product, The Right C. , The Right C ... than traditional vitamin C supplements. At the trade show, Doctor C had the opportunity ...
(Date:1/20/2017)... ... 20, 2017 , ... ATP Science, an Australian-based company focused ... the January ECRM Trade Show in Hilton Head, SC, benefiting from outstanding meetings ... of supplements that keep the body functioning at its peak performance by providing ...
(Date:1/20/2017)... ... January 20, 2017 , ... "TransFlare 4K Mystique comes ... of Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... Utilizing the Dragon Sensor,TransFlare 4K Mystique lens flare and light leak transitions have a ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , Jan. 19, 2017  Stealth BioTherapeutics Inc. ( ... treat mitochondrial dysfunction, today announced new additions to its ... as Chief Medical Officer, and Daniel Geffken ... that Jim Carr , Pharm.D. has been promoted ... are pleased to welcome Doug and Daniel to our ...
(Date:1/19/2017)... 19, 2017 James ... & Haematology, 2016;12(Suppl 2):3-8; http://www.touchoncology.com/articles/optimising-clinical-outcomes-gastrointestinal-cancers-through-inhibiting-angiogenesis-and ... ... Published recently in a supplement to European ... touchONCOLOGY, an article by James Gilbart ...
(Date:1/19/2017)... , January 19, 2017 ... Otsuka in the Milner Therapeutics Consortium   ... in Cambridge   ... PFE ) as a partner to the ... Consortium, which enables the efficient transfer of materials between ...
Breaking Medicine Technology: